A Consultant Neurologist at Tallaght University Hospital has called on the HSE to allow for access to a drug that can help ...

Clinicians have few ways to tell if lecanemab is working in any given patient. A new study of blood proteins offers a first look at what a blood test might track.

The Baron Health Care Fund reported performance details for the quarter ended September 30, 2026. Read the full analysis for ...

New Delhi, Oct 26 (PTI) Forgetfulness may accompany ageing, but persistent memory loss, repeating questions and difficulty performing familiar tasks could signal dementia and should not be dismissed ...

NHS diabetes and ADHD drugs will soon be tested on Alzheimer’s patients in a breakthrough new clinical trial. The move aims ...

Acumen Pharmaceuticals aims for 30% iADRS slowing in its Phase 2 Alzheimer's trial, setting a Phase 3-level bar for mid-stage ...

The new tests can reveal changes in the brain years before symptoms appear—but experts caution that they may not help ...

Local hospitals are expanding access to novel treatments for Alzheimer’s disease to offer new care options to those in ...

“For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer.” ...

"I'm still young, but I've been forgetting things more often lately.""I'm making more mistakes at work, or things I used to ...

Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock ...

Race and ethnicity are tied to who receives antiamyloid drugs for mild cognitive impairment and dementia, even after adjusting for neighborhood vulnerability, a study shows.